CXCL9 and neoplasm: Their combination therapy, involving antiangiogenic tyrosine kinase inhibitors (TKIs) and therapeutic vaccines, elevated tumor-infiltrating lymphocytes (TILs), such as tumor antigen-specific CD8 T cells and upregulated the expressions of activation markers including ENG, CXCL-9, FAS-L, and CD31 in tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs), leading to decreased tumor volumes and increased the number of tumor-free mice.